254 related articles for article (PubMed ID: 15509675)
1. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA
J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
[TBL] [Abstract][Full Text] [Related]
2. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
3. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase A in Barrett's carcinogenesis.
Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
[TBL] [Abstract][Full Text] [Related]
5. Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma.
Brundler MA; Harrison JA; de Saussure B; de Perrot M; Pepper MS
J Clin Pathol; 2006 Feb; 59(2):191-5. PubMed ID: 16443737
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
[TBL] [Abstract][Full Text] [Related]
7. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
9. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.
Whittles CE; Biddlestone LR; Burton A; Barr H; Jankowski JA; Warner PJ; Shepherd NA
J Pathol; 1999 Apr; 187(5):535-40. PubMed ID: 10398118
[TBL] [Abstract][Full Text] [Related]
11. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus.
Fortun PJ; Anagnostopoulos GK; Kaye P; James M; Foley S; Samuel S; Shonde A; Badreldin R; Campbell E; Hawkey CJ; Ragunath K
Aliment Pharmacol Ther; 2006 Mar; 23(6):735-42. PubMed ID: 16556175
[TBL] [Abstract][Full Text] [Related]
12. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
13. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
14. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
Ling FC; Baldus SE; Khochfar J; Xi H; Neiss S; Brabender J; Metzger R; Drebber U; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Histopathology; 2007 Jan; 50(2):203-9. PubMed ID: 17222248
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk in Barrett's oesophagus.
Dias Pereira A; Suspiro A; Chaves P
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
[TBL] [Abstract][Full Text] [Related]
16. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
17. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
Sonoda R; Naomoto Y; Shirakawa Y; Fujiwara Y; Yamatsuji T; Noma K; Tanabe S; Takaoka M; Gunduz M; Tsujigiwa H; Nagatsuka H; Ohara N; Yoshino T; Takubo K; Vieth M; Tanaka N
Histopathology; 2010 Jul; 57(1):90-100. PubMed ID: 20653782
[TBL] [Abstract][Full Text] [Related]
18. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia.
Cameron AJ; Souto EO; Smyrk TC
Am J Gastroenterol; 2002 Jun; 97(6):1375-80. PubMed ID: 12094853
[TBL] [Abstract][Full Text] [Related]
19. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
20. Barrett's oesophagus: the new endoscopic modalities have a future.
Deviere J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]